 |
|
|
|
|
|
RayVa™
RayVa™ (alprostadil and DDAIP for treatment of Raynaud's Syndrome Secondary to Scleroderma; IND to be filed for SPA Phase III)
Raynaud's syndrome refers to a disorder in which the fingers or toes (digits) suddenly experience decreased blood circulation, and is characterized by color changes of the skin of the digits upon exposure to cold or emotional stress. The prevalence of Reynaud's syndrome in the general U.S. population is estimated to vary from 3-10% . Scleroderma affects only 75,000 to 100,000 people in the US and Raynaud's affects 90% of Scleroderma patients. Women are seven times more likely to develop the condition than men. For most patients, Raynaud's syndrome is an inconvenience. However, chronic recurrent cases of Raynaud's syndrome can result in atrophy of the skin, subcutaneous tissues and muscle. In rare cases it can cause ulceration and ischemic gangrene.
Apricus Bio has significant experience developing stable alprostadil products. In pre-clinical testing, RayVa™ showed significant improvement in blood flow over the placebo cream. Apricus Bio believes RayVa™ can be a very useful alternative to currently available prostanoids and other medications used to treat Raynaud's Syndrome Secondary to Scleroderma.
|
|
|
|
| |
|
|
|
IND stage product